A 2007 article showed the efficacy of a mGlu2/3 orthosteric agonist in patients with schizophrenia and provided hope for new treatment solutions [57], as described in the review “Schizophrenia drug says goodbye to dopamine” [115]. This evidence concerns the gene GRM2 and schizophrenia.